Isolated cardiac sarcoidosis in heart transplantation

T. I. Chang, N. H. Chi, N. K. Chou, C. I. Tsao, H. Y. Yu, Y. S. Chen, S. S. Wang

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: Heart transplantation is the ultimate treatment for end-stage heart failure. Cardiac sarcoidosis has rarely been reported in heart transplantation worldwide. Their long-term prognosis after heart transplantation is unknown. Herein we have presented clinical and pathological observations among heart transplantation patients with isolated cardiac sarcoidosis. Methods: From 1987 to 2011, we performed 411 heart transplantations including five patients retrospectively reviewed due to the presence of sarcoidosis and giant-cell cardiomyopathy in the recipient heart. Results: Among the heart transplantations from 2003 to 2011, the four male and one female patients were ages 31 to 40 years. None of them had extra-cardiac sarcoidosis. All five subjects presented with dilated cardiomyopathy with patent coronary arteries. The commonest clinical presentations were atrioventricular block, ventricular arrhythmia, electrocardiographic findings of ST elevations, and poor left ventricular ejection fractions (17%-23%). All patients survived without allograft heart failure to date with the longest survivor at 8 years postoperatively. No recurrence of sarcoidosis has been observed clinically or among the post-heart transplantation endomyocardial biopsies. Conclusion: Heart transplantation is a useful treatment for isolated cardiac sarcoidosis patients suffering end-stage heart failure. Often the diagnosis is difficult to establish before heart transplantation despite endomyocardial biopsy. No recurrence of sarcoidosis was observed among the allografted hearts.

Original languageEnglish
Pages (from-to)903-906
Number of pages4
JournalTransplantation Proceedings
Volume44
Issue number4
DOIs
Publication statusPublished - May 2012
Externally publishedYes

Fingerprint

Heart Transplantation
Sarcoidosis
Heart Failure
Biopsy
Recurrence
Atrioventricular Block
Dilated Cardiomyopathy
Giant Cells
Cardiomyopathies
Stroke Volume
Allografts
Survivors
Cardiac Arrhythmias
Coronary Vessels
Therapeutics

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Chang, T. I., Chi, N. H., Chou, N. K., Tsao, C. I., Yu, H. Y., Chen, Y. S., & Wang, S. S. (2012). Isolated cardiac sarcoidosis in heart transplantation. Transplantation Proceedings, 44(4), 903-906. https://doi.org/10.1016/j.transproceed.2012.01.087

Isolated cardiac sarcoidosis in heart transplantation. / Chang, T. I.; Chi, N. H.; Chou, N. K.; Tsao, C. I.; Yu, H. Y.; Chen, Y. S.; Wang, S. S.

In: Transplantation Proceedings, Vol. 44, No. 4, 05.2012, p. 903-906.

Research output: Contribution to journalArticle

Chang, TI, Chi, NH, Chou, NK, Tsao, CI, Yu, HY, Chen, YS & Wang, SS 2012, 'Isolated cardiac sarcoidosis in heart transplantation', Transplantation Proceedings, vol. 44, no. 4, pp. 903-906. https://doi.org/10.1016/j.transproceed.2012.01.087
Chang, T. I. ; Chi, N. H. ; Chou, N. K. ; Tsao, C. I. ; Yu, H. Y. ; Chen, Y. S. ; Wang, S. S. / Isolated cardiac sarcoidosis in heart transplantation. In: Transplantation Proceedings. 2012 ; Vol. 44, No. 4. pp. 903-906.
@article{d49dfc90b57f40f6b95151779986ce93,
title = "Isolated cardiac sarcoidosis in heart transplantation",
abstract = "Background: Heart transplantation is the ultimate treatment for end-stage heart failure. Cardiac sarcoidosis has rarely been reported in heart transplantation worldwide. Their long-term prognosis after heart transplantation is unknown. Herein we have presented clinical and pathological observations among heart transplantation patients with isolated cardiac sarcoidosis. Methods: From 1987 to 2011, we performed 411 heart transplantations including five patients retrospectively reviewed due to the presence of sarcoidosis and giant-cell cardiomyopathy in the recipient heart. Results: Among the heart transplantations from 2003 to 2011, the four male and one female patients were ages 31 to 40 years. None of them had extra-cardiac sarcoidosis. All five subjects presented with dilated cardiomyopathy with patent coronary arteries. The commonest clinical presentations were atrioventricular block, ventricular arrhythmia, electrocardiographic findings of ST elevations, and poor left ventricular ejection fractions (17{\%}-23{\%}). All patients survived without allograft heart failure to date with the longest survivor at 8 years postoperatively. No recurrence of sarcoidosis has been observed clinically or among the post-heart transplantation endomyocardial biopsies. Conclusion: Heart transplantation is a useful treatment for isolated cardiac sarcoidosis patients suffering end-stage heart failure. Often the diagnosis is difficult to establish before heart transplantation despite endomyocardial biopsy. No recurrence of sarcoidosis was observed among the allografted hearts.",
author = "Chang, {T. I.} and Chi, {N. H.} and Chou, {N. K.} and Tsao, {C. I.} and Yu, {H. Y.} and Chen, {Y. S.} and Wang, {S. S.}",
year = "2012",
month = "5",
doi = "10.1016/j.transproceed.2012.01.087",
language = "English",
volume = "44",
pages = "903--906",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "4",

}

TY - JOUR

T1 - Isolated cardiac sarcoidosis in heart transplantation

AU - Chang, T. I.

AU - Chi, N. H.

AU - Chou, N. K.

AU - Tsao, C. I.

AU - Yu, H. Y.

AU - Chen, Y. S.

AU - Wang, S. S.

PY - 2012/5

Y1 - 2012/5

N2 - Background: Heart transplantation is the ultimate treatment for end-stage heart failure. Cardiac sarcoidosis has rarely been reported in heart transplantation worldwide. Their long-term prognosis after heart transplantation is unknown. Herein we have presented clinical and pathological observations among heart transplantation patients with isolated cardiac sarcoidosis. Methods: From 1987 to 2011, we performed 411 heart transplantations including five patients retrospectively reviewed due to the presence of sarcoidosis and giant-cell cardiomyopathy in the recipient heart. Results: Among the heart transplantations from 2003 to 2011, the four male and one female patients were ages 31 to 40 years. None of them had extra-cardiac sarcoidosis. All five subjects presented with dilated cardiomyopathy with patent coronary arteries. The commonest clinical presentations were atrioventricular block, ventricular arrhythmia, electrocardiographic findings of ST elevations, and poor left ventricular ejection fractions (17%-23%). All patients survived without allograft heart failure to date with the longest survivor at 8 years postoperatively. No recurrence of sarcoidosis has been observed clinically or among the post-heart transplantation endomyocardial biopsies. Conclusion: Heart transplantation is a useful treatment for isolated cardiac sarcoidosis patients suffering end-stage heart failure. Often the diagnosis is difficult to establish before heart transplantation despite endomyocardial biopsy. No recurrence of sarcoidosis was observed among the allografted hearts.

AB - Background: Heart transplantation is the ultimate treatment for end-stage heart failure. Cardiac sarcoidosis has rarely been reported in heart transplantation worldwide. Their long-term prognosis after heart transplantation is unknown. Herein we have presented clinical and pathological observations among heart transplantation patients with isolated cardiac sarcoidosis. Methods: From 1987 to 2011, we performed 411 heart transplantations including five patients retrospectively reviewed due to the presence of sarcoidosis and giant-cell cardiomyopathy in the recipient heart. Results: Among the heart transplantations from 2003 to 2011, the four male and one female patients were ages 31 to 40 years. None of them had extra-cardiac sarcoidosis. All five subjects presented with dilated cardiomyopathy with patent coronary arteries. The commonest clinical presentations were atrioventricular block, ventricular arrhythmia, electrocardiographic findings of ST elevations, and poor left ventricular ejection fractions (17%-23%). All patients survived without allograft heart failure to date with the longest survivor at 8 years postoperatively. No recurrence of sarcoidosis has been observed clinically or among the post-heart transplantation endomyocardial biopsies. Conclusion: Heart transplantation is a useful treatment for isolated cardiac sarcoidosis patients suffering end-stage heart failure. Often the diagnosis is difficult to establish before heart transplantation despite endomyocardial biopsy. No recurrence of sarcoidosis was observed among the allografted hearts.

UR - http://www.scopus.com/inward/record.url?scp=84860743118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860743118&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2012.01.087

DO - 10.1016/j.transproceed.2012.01.087

M3 - Article

C2 - 22564580

AN - SCOPUS:84860743118

VL - 44

SP - 903

EP - 906

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 4

ER -